Through their collaboration, ZEISS and EDGE Biotechnologies aim to pioneer advanced biopharma solutions and reshape the role of bioimaging from a “niche tool” to a “core quantitative decision-making engine” in the biopharma industry.
By combining the leadership of ZEISS in optical innovation with EDGE’s assays and AI analytics, the collaboration aspires to deliver end-to-end solutions to customers that simplify their workflows, enhance their research capabilities, and enable faster decisions – as well as complementing customers’ existing AI missions with novel data sets.
The collaboration aims to leverage the combined strength of the two companies to deliver an integrated solution that positions bioimaging as a strategic enabler in the industry. At the core of the collaboration is a shared focus on quantitative bioimaging. It offers customers the possibility to move beyond images to standardized, assay-driven insights. Using EDGE-developed assays and AI-driven analytics, high-quality microscopy data is transformed into quantitative descriptions that inform R&D decisions, reducing uncertainty and timelines.
